British Journal of Dermatology
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
Siebenhaar F, Altrichter S, Bonnekoh H, et al.
Results from a single-ascending and multidose clinical trial of lirentelimab in patients with indolent systemic mastocytosis demonstrate that lirentelimab was well tolerated and led to improved symptoms and quality of life. Option 2: Learn about a first-in-human study of lirentelimab for indolent systemic mastocytosis.
Previous Article
- • Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: a nationwide multicenter retrospective analysis.
- • Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy
- • Plasma protein profiling to discern indolent from advanced systemic mastocytosis
- • Indolent systemic mastocytosis (ISM) without skin lesions as a recurrent anaphylaxis: a case report study.
- • Safety of a mRNA COVID-19 vaccine in patients with indolent systemic mastocytosis.
- • Avapritinib versus placebo in indolent systemic mastocytosis.
- • The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing.
- • Genome-wide DNA methylation and gene expression in patients with indolent systemic mastocytosis.
- • Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
- • Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.
- • Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms.
- • The international consensus classification of mastocytosis and related entities.
- • Developments in Clinical and Translational IgAN Research
- • The CURE-CKD Registry
- • Non-Invasive Diagnostic Tools in IgA Nephropathy
- • Efficacy and Safety of Endothelin A Receptor Antagonists in IgA Nephropathy
- • Hydroxychloroquine Regulates Intestinal Flora and Glycosyltransferase Activity in Rats With IgA Nephropathy
- • Genetic Implications for IgA Nephropathy Therapy
- • Global Epidemiology of IgA Nephropathy
- • The Mastocytosis Control Test for Assessing Disease Control
- • Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan
- • The Safety and Effectiveness of Palbociclib in Clinical Practice
- • Determinants of HER2-Targeted Therapy Use in Metastatic HR-/HER2+ Breast Cancer
- • Equity of Care Across Metastatic Breast Cancer Treatment
- • Tumor Growth Rate and Survival in Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- • Patient-Reported Outcomes From DESTINY-Breast04
- • Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
- • Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
- • Animal Models in Metastatic Breast Cancer Immunotherapy Research
- • PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
- • Smartphone-Based Monitoring of Chronic Kidney Disease
- • The Validated Mastocytosis Control Test for Measuring Disease Control
